DNA Topoisomerase II-α Regulated by miR-22-5p Promotes Hepatocellular Carcinoma Invasion and Migration through the Hippo Pathway

Haichao Zhao,1,2 Changzhou Chen,1,2 Huangqin Song,1 Rongyi Qin,1 Xiaoxiao Wang,1 Qizu He,1 Feng Li,1 Haoliang Zhao,1 and Yanjun Li1

1Shanxi Bethune Hospital, Shanxi Medical University, Taiyuan 030032, China
2Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai 300032, China

Correspondence should be addressed to Haoliang Zhao; haoliangzhao@hotmail.com and Yanjun Li; liyjjisheng1017@163.com

Received 11 August 2022; Accepted 27 September 2022; Published 17 October 2022

Academic Editor: Md Sayed Ali Sheikh

Copyright © 2022 Haichao Zhao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

DNA topoisomerases (TOPs) are dysregulated in various types of cancer. However, how TOP II-alpha (TOP2A) contributes to hepatocellular carcinoma (HCC) progression remains elusive. Cohort analysis revealed that the increased expression of TOP2A was associated with poor clinical outcomes and TOP2A was significantly upregulated in HCC tissues and cell lines. In vitro, TOP2A expression level is related to cell invasion and migration, which may be due to the alteration of epithelial-mesenchymal transition by the TOP2A. Moreover, we used verteporfin (a Hippo inhibitor) to test how the Hippo pathway promotes the effect of TOP2A on the HCC phenotype and found that TOP2A induces tumor progression through the Hippo pathway. Finally, miR-22-5p inhibited tumor progression by sponging TOP2A.

1. Introduction

Primary liver cancer (PLC) is the sixth most prevalent type of cancer and the fourth leading cause of cancer-related deaths worldwide [1]. Due to the insidious onset and rapid progression of PLC, many patients are diagnosed at an advanced stage [2, 3]. Furthermore, 75% of PLC patients have hepatocellular carcinoma (HCC) [4]. Therefore, identification of cancer-dependent genes that promote HCC progression is essential for HCC treatment.

DNA topoisomerase II-alpha (TOP2A) encodes DNA topoisomerase, which is the key enzyme for the selective cutting, rearrangement, and reconnection of DNA strands [5]. TOP2A is necessary for managing DNA supercoiling and chromosomal separation. It plays important roles in mitosis, including chromosome separation during DNA transcription and replication, chromatin compaction, and torsional stress relief [6]. A previous meta-analysis found that mutation (amplification or deletion) of the TOP2A gene leads to shorter survival time of cancer patients [7]. The abnormal expression of TOP2 protein was significantly associated with tumor resistance to adriamycin [8]. The overexpression of TOP2A results in accelerated tumor progression and a poor prognosis in lung adenocarcinoma [9]. High TOP2A expression is a favorable prognostic factor in colorectal cancer [10]. Currently, there are no available medications that specifically target TOP2A and its related pathways. Anthracycline medications are the only available empirical drugs, which showed poor efficacy in clinical practice [11].

Dysregulation of the Hippo signaling pathway promotes cancer progression [12, 13]. Moya et al. [14] found that the activity of yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ) in tumors was linked to the progression of liver tumors. The abnormal activation of the Hippo pathway upregulated androgen receptor (AR) activity in metastatic prostate cancer and reduced the
Genetic alteration
- Missense mutation (unknown significance)
- Splice mutation (unknown significance)
- Truncating mutation (unknown significance)
- Structural variant (unknown significance)
- mRNA high
- mRNA low
- No alterations
- Amplification
- Deep deletion

Gene dendrogram and module colors

Dynamic tree cut
Merged dynamics

Module-Trait relationships

Helicase activity
- Single-stranded DNA binding
- 3’–5’ DNA helicase activity
- DNA helicase activity
- DNA replication origin binding
- Kinetochore
- Condensed chromosome
- Condensed chromosome, centromeric region
- Chromosome, centromeric region
- Chromosomal region
- Mitotic sister chromatid segregation
- Nuclear division
- Organelle fission
- Chromosome segregation
- Mitotic nuclear division

Figure 1: Continued.
overall survival (OS) of patients [15]. Through enrichment analysis, we identified that TOP2A regulated the cell cycle and DNA replication through the Hippo signaling pathway.

In this study, we aimed to explore the TOP2A tumor-promoting effects and elucidate whether TOP2A regulates the activity of YAP1 in the Hippo signaling pathway by binding to β-catenin to exert biological effects. Furthermore, we aimed to explore the mechanisms underlying the high expression of TOP2A and identify the possible targeted drugs.

2. Materials and Methods

2.1. Data Resource. The mRNA expression and clinical data were obtained from the Cancer Genome Atlas (TCGA) liver cancer dataset (https://www.proteinatlas.org/). We obtained 374 HCC tissue samples and 50 normal liver tissue samples. Fifty nontumor liver tissue samples and 50 HCC tissue samples were obtained from the same patients. Of the 374 participants, 3 had missing data on T stage. Moreover, the data of 110 normal liver tissue samples were obtained from Genotype Tissue Expression (https://xenabrowser.net/hub/). The biological relationship between the two genes was analyzed using Pearson’s correlation coefficient (r). The moderate or high expression of TOP2A coexpressed genes was identified based on the screening criteria (P < 0.001, |r| > 0.5).

2.2. Weighted Gene Coexpression Network Analysis (WGCNA). The median TOP2A mRNA level was used as an external attribute to categorize the samples into elevated and reduced expression groups, from which the correspond-
Figure 2: Continued.
2.5. RNA Extraction and qRT-PCR. TRIzol reagent was used for isolation of total RNA from the tissues and cells (Invitrogen, CA, USA). We used the RT kit M5 Sprint qPCR with gDNA remover (Mei5bio, China) to reverse-transcribe mRNA into cDNA. The first-strand cDNA of miRNA TransScript SuperMix (TransGen Biotech, China) was used for the synthesis of miRNA cDNA. qRT-PCR was performed on a 7500 Fast RT-PCR System (Applied Biosystems, CA, USA) using the SYBR Premix EX Taq II (Takara, Tokyo, Japan). The U6 served as the control for standardizing miRNA, and ATCB was used as the control to standardize mRNA (Table S1).

2.6. Western Blot Analysis. Radioimmunoprecipitation assay lysis buffer was used for isolation of proteins from cells (Boster, Wuhan, China), while a bicinechonic acid kit (Boster, Wuhan, China) was used for determination of protein concentration; the protein samples were heated after being combined with a loading buffer (Boster) at a 5:1 ratio. The proteins in the gels were translocated in polyvinylidene difluoride membranes after separation by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The membrane was incubated with primary antibodies after blocking with 5% nonfat milk powder for 2 h at room temperature (RT). The primary antibodies were used for the analysis after incubating the proteins with the following secondary antibodies: rabbit anti-TOP2A (1:2,500; CST, 12286), rabbit anti-E-cadherin (1:10,000) (ab40772), rabbit anti-N-cadherin (1:10,000) (ab18203), rabbit anti-vimentin (1:5,000; Abcam ab92547), rabbit anti-Snail1 (1:1,000; Boster, PB0449), rabbit anti-Snail2 (1:2,000; Boster, PB9439), rabbit anti-β-actin (1:10,000; Boster, BM0627), and rabbit anti-GAPDH (1:2,000; Boster, A00227-1). The secondary antibodies (1:10,000) were purchased from Proteintech, China. The experiments were repeated three times. Finally, the amplified chemiluminescent system was used to visually detect the signal.

2.7. Immunohistochemistry. After initial treatment with 4% paraformaldehyde, the tumor tissue was embedded in paraffin and then sliced into 5μm thick sections. The sections were blocked with 10% goat serum and incubated overnight with anti-TOP2A (1:200, 12286, CST) antibody at 4°C. After washing with PBS, the tissue slices were incubated at RT for 1 h with a secondary antibody that had been conjugated with anti-rabbit or anti-mouse horseradish peroxidase. The paraffin sections were stained with diaminobenzidine and hematoxylin. The IHC slides were observed under a microscope (Nikon, Japan).

2.8. Wound Healing Assay. In wound healing studies, cells (5×10⁴/500 μl) in the logarithmic growth phase were grown until reach 100% confluence was reached in 24-well plates over a 24-hour course. In the middle of each well, a scratch was made in the HCC cell layer using a 10 μl micropipette tip (denoted as 0 h). To inhibit proliferation, the cells were cultivated in DMEM containing 1% FBS. The HCC cells were gently washed with PBS and cultivated for another
Relative mRNA expression of TOP2A

- L02
- MHCC97L
- HCCLM3
- SMMC7721
- BEL-7404
- HepG2
- SK-HEP-1
- Huh7

(b) Relative protein expression of TOP2A

- BEL-7404
- MHCC97L

(c) 

- BEL-7404
- MHCC97L

Figure 3: Continued.
Figure 3: Continued.
24 h at 37°C in fresh DMEM containing 1% FBS. An inverted light microscope (magnification, 200×; Leica Microsystems, Inc.) was used to photograph the scratched cells. We quantified the extent to which the cells could migrate. We assessed the progress of wound healing and compared the results with the initial measurements. All experiments were independently replicated three times.

2.9. Transwell Assay. The invasion ability of HCC cells was evaluated by Transwell assay. Serum-free medium was used for cell starvation for 24 h. HCC cells 2×10⁴ cells in 200 μl serum-free media were implanted in the upper chamber (8.0 μm pore size; Corning, Inc.) that was precoated for 8 h with 90 μl Matrigel (BD Biosciences) at 37°C. The lower chamber was then refilled with 600 μl of Roswell Park Memorial Institute 1640 medium (Boster, Wuhan) with 10% FBS and incubated at 37°C for 24 h. Approximately 4% polymethanol (Boster, Wuhan) was used to fix the upper chambers for 30 min before being dyed with 0.1% crystal violet for half an hour at RT. An inverted light microscope was used to photograph the cells that had passed through the membrane and infiltrated into the top chamber. The number of invading or migrating cells was determined by selecting five fields at random.

2.10. Dual-Luciferase Reporter Assay. MHCC97L cells were plated in 24-well plates at a density of 1×10⁵ cells/well in 0.5 ml. To assess whether miR-22-5p targets TOP2A, 10 ng of wild-type miRNA was transfected into the cells. (TOP2A 3'UTR-WT) or mutant type (TOP2A 3'UTR-Mut) plasmids coexpressing firefly luciferase, 20 pmol of miR-22-5p mimic or NC mimic, and 10 ng of pRL-TK plasmid (Promega, Madison, WI, USA). Lipofectamine RNAi MAX reagent (HANBIO, Wuhan, China) was used to transfect the cells according to the manufacturer’s protocol. Using the Dual-Glo luciferase reporter assay system (Promega), the levels of firefly luciferase was compared to that of Renilla luciferase activity, and the F-Luc/R-Luc was determined. Each transfection was performed in triplicate.

2.11. Molecular Docking. In this study, Schrödinger (LSA, USA) was used to simulate and dock the screened drugs. The two-dimensional (2D) structure mol2 files of the small molecules were retrieved from DrugBank (https://www.drugbank.com/). The LigPrep module was employed for ligand processing with a pH value of 7.0 ± 2.0. Then, the tautomer status was determined using the Epik program, while the rest of the parameters were used as the default settings of the system. The molecules were optimized using the OPLS2005 force field. The TOP2A number was 1LWZ, according to the keyword search in the Protein Data Bank (PDB, https://www.rcsb.org/). First, Schrödinger’s Protein Preparation Wizard module was used for preparatory processing of the protein structure. The system was then optimized using the OPLS3 force field. To produce the ground-state tautomer, the cocrystal ligand pH was adjusted.
Figure 4: TOP2A overexpression promotes HCC invasion and migration in vitro. (a) TOP2A expression in SK-HEP-1 cells transfected with TOP2A was determined by RT-qPCR. (b) Western blot analysis of indicated HCC cells (SK-HEP-1) transfected with TOP2A-vector (Ctrl group) or TOP2A (TOP2A group). (c) Transwell invasion assay of HCC cells transfected with Ctrl or TOP2A. The bar graphs show the number of migrating and invasive cells after 24 h. (d) Representative images of wound healing assays after scratch wounding of the cells described. (e) Western blot analysis was performed to detect the epithelial mesenchymal protein expression in HCC cells transfected with Ctrl or TOP2A. Data are shown as mean ± SEM; ***P < 0.001, **P < 0.01, and *P < 0.05.
Figure 5: Continued.
Figure 5: Continued.
TOP2A vs. YAP1, 374 sample (LIHC)
Data source: starBase v3.0 project

Regression \( y = 0.1657x + 2.5792 \)
\[ r = 0.312, \quad p - \text{value} = 7.07\times 10^{-10} \]

TOP2A vs. TAZ, 374 samples (LIHC)
Data source: starBase v3.0 project

Regression \( y = 0.0666x + 2.1926 \)
\[ r = 0.189, \quad p - \text{value} = 2.33\times 10^{-04} \]

Figure 5: Continued.
to 7.0 ± 3.0. The Receptor Grid Generation module was used to determine the docking area, while the space position defined the active pocket, which was used as the center of the grid. The ligand-docking module performs ligand docking and sets the conformation and flexibility of the ligand molecule. Finally, various binding modes were scored and sorted based on the molecular energy of docking, and the docking conformation of the molecule was determined based on the lowest docking energy. All small molecules in the small-molecule active ingredient database established above were selected as candidate ligands and docked to the optimized TOP2A protein. Small-molecule active ingredients with high scores were selected. The reported small-molecule active ingredients were selected through literature research to optimize the docking results, narrow the scope of subsequent experimental verification, and improve the pertinence, accuracy, and success rate of small-molecule active component screening.

2.12. Statistical Analysis. Data obtained from at least three independent experiments were analyzed using GraphPad Prism 8 (GraphPad Software, Inc., San Diego, CA, USA). The statistical significance between two groups was analyzed using Student’s t-test. Multiple groups were compared using one-way analysis of variance and Tukey’s post hoc test. Means ± standard deviation (SD) were used to display all data. A P value of < 0.05 was considered significant.

3. Results

3.1. High Expression of TOP2A as a Predictor of Poor Clinical Outcomes in HCC Patients. TOP2A was highly expressed in a variety of tumors (Figure S1), particularly HCC (Figure S2A–C), and the mutation rate in HCC was 76% (Figure 1(a)). Significant differences were observed in the T stage, pathological stage, histological grade, and alpha-fetoprotein (AFP) between the TOP2A<sup>high</sup> and TOP2A<sup>low</sup> groups (Table S2). The TOP2A expression levels in T3 and T4 samples were higher than those in T1 and T2 samples (Figure S2D). TOP2A expression was correlated with clinical stage, histological grade, and AFP level (Figure S2E–H). The receiver operating characteristic curve analysis established a good diagnostic value for TOP2A (AUC = 0.951, Figure S2I). The Kaplan-Meier plotter demonstrated that the OS, disease-specific survival, and progression-free interval of patients with high TOP2A expression were reduced (Figure S2J–L). The univariate and multivariate Cox regression analyses revealed that TOP2A expression can be used as an independent predictor of OS (Table S3). Results of the weighted gene coexpression network analysis
Figure 6: Continued.
Figure 6: Continued.
Figure 6: miR-22-5p inhibits the cancer-promoting effect of TOP2A. (a) Venn diagram shows the miRNAs predicted by the database that can interact with TOP2A mRNA. (b) qRT-PCR revealed the miRNA expression in liver cancer tissues and ADT. (c) qRT-PCR showed that the expression level of TOP2A mRNA in the HCC cell line (MHCC97L) transfected with miRNAs. (d) Western blot analysis demonstrated the TOP2A protein expression in the HCC cell line (MHCC97L and BEL-7404) transfected with miRNAs (e) RNA levels of miR-22-5p, GAPDH, and U6 in the nuclear and cytoplasmic fractions of MHCC97L cells. (f) Wound healing assays of HCC cells (MHCC97L and BEL-7404) transfected with miR-Ctrl or miR-22-5p mimics. (g) Transwell invasion assay of HCC cells (MHCC97L and BEL-7404) transfected with miR-Ctrl or miR-22-5p mimics. (h) Western blotting was utilized for detection E-cad and Hippo pathway-associated protein expression in HCC cells (MHCC97L and BEL-7404) transfected with miR-Ctrl or miR-22-5p mimics. (i) Dual-luciferase reporter assay to detect the activity of LUC-TOP2A-wt or LUC-TOP2A-mutant in MHCC97L cells after overexpression of miR-22-5p. The predicted binding site of miR-22-5p in TOP2A. The mutated site of miR-22-5p in TOP2A. The predicted binding site of miR-22-5p in TOP2A. The wild-type and a mutated type of binding site between miR-22-5p and TOP2A. Data are shown as mean ± SEM; ***P < 0.001, **P < 0.01, and *P < 0.05.

(WGCNA) revealed that TOP2A-related genes were enriched in DNA replication, oocyte meiosis, and the p53 signaling pathway (Figures 1(b)–1(e)). Therefore, TOP2A highly expressed in liver cancer was closely related to high disease grade, late disease stage, and poor prognosis.

3.2. Level of TOP2A Expression in HCC and Its Relation to the Tumor Volume. IHC analysis confirmed a higher level of TOP2A in HCC (Figures 2(a) and 2(b)). RNA and protein were extracted from 18 pairs of HCC tissue samples. Cancer tissues had higher TOP2A mRNA and protein expression levels than the adjacent non-tumor tissues (ANT), as shown on qRT-PCR and western blot analysis (Figures 2(c) and 2(d)). The average tumor diameter in the TOP2A-high group was higher than that in the TOP2A-low group (Figure 2(e)). These results demonstrated that the TOP2A expression levels were significantly increased in HCC tissues and were associated with the tumor volume.

3.3. Knockdown of TOP2A Suppressing HCC Invasion and Migration In Vitro. To determine the biological functions of TOP2A in HCC cells, we initially detected the expression of TOP2A in L02 and 8 HCC cell lines (MHCC97L, MHCC97H, HCCLM3, SMCC7721, BEL-7404, HepG2, SK-HEP-1, and Huh7). The TOP2A mRNA and protein expression levels in HCC cell lines were higher than those in L02 cells (Figures 3(a) and 3(b)). MHCC97L and BEL-7404 demonstrated the highest endogenous mRNA and protein expression levels of TOP2A, whereas HepG2 and SK-HEP-1 cell lines demonstrated the lowest TOP2A expression levels (Figures 3(a) and 3(b)). TOP2A knockdown and control MHCC97L and BEL-7404 cell lines were constructed (Figures 3(c) and 3(d)). Results of Transwell and wound healing assays showed that the invasion and migration of HCC cell lines were inhibited by si-TOP2A (Figures 3(e) and 3(f)). Silencing of TOP2A increased the E-cadherin expression, accompanied by the downregulation of N-cadherin, vimentin, Snail1, and Snail2 (Figure 3(g)). These results indicate that TOP2A enhances HCC cell invasion and migration via epithelial-mesenchymal transition (EMT).

3.4. TOP2A Overexpression Promotes Invasion and Migration of HCC Cells. To further investigate the effects of TOP2A on HCC, we transfected SK-HEP-1 (TOP2A low expression) with the empty vector plasmid (Ctrl group) and the TOP2A recombinant plasmid (TOP2A group) (Figures 4(a) and 4(b)). Results of Transwell assays showed that the TOP2A overexpression increased the invasive ability of SK-HEP-1 cells (Figure 4(c)). Similarly, the recombinant TOP2A plasmid induced the production of SK-HEP-1 cells with stronger migration ability (Figure 4(d)). Western blot analysis results showed that the overexpression of TOP2A decreased the E-cadherin expression and increased the expression of N-cadherin and vimentin, which may have promoted the EMT process by increasing the levels of Snail1 and Snail2 (Figure 4(e)). These results indicated that TOP2A promotes the invasion and migration of HCC cells.

3.5. TOP2A Affecting HCC Tumor Progression through Hippo Signaling Pathway. Oncogenes often promote tumor progression by regulating the signaling pathways [12, 13]. Kyoto Encyclopedia of Genes and Genomes (KEGG)
Figure 7: Continued.
Figure 7: TOP2A overexpression reverse the effect of miR-22-5p. (a, b) qRT-PCR and western blot analysis exposed the TOP2A mRNA and protein level of HCC cell lines (MHCC97L and BEL-7404) transfected with miR-Ctrl+vector, miR-22-5p mimics+vector, or miR-22-5p mimics+TOP2A. (c) Wound healing assays of HCC cells treated with miR-Ctrl+vector, miR-22-5p+vector, and miR-22-5p+TOP2A. (d) Transwell invasion assay of HCC cells treated with miR-Ctrl+vector, miR-22-5p+vector, and miR-22-5p+TOP2A. The bar graphs show the number of migrating and invasive cells after 24 h. Data are shown as mean ± SEM; ***P < 0.001, **P < 0.01, and *P < 0.05.
enrichment analysis showed that TOP2A was associated to cell cycle, progesterone-mediated oocyte maturation, p53 signaling pathway, and Hippo signaling pathway (Figure 5(a)). Therefore, we speculated that TOP2A exerted tumor-promoting effects through the Hippo pathway. Subsequently, we verified the correlation between TOP2A and key proteins of the Hippo signaling pathway using ENCORI and found that TOP2A was associated to aSP: standard precision; bXP: extraprecision.

Therefore, we explored whether miRNAs a

expression was associated with TOP2A levels (r = −0.223, P = 4.78e − 2; Figure S4C). The expression of the four miRNAs was lower in HCC tissues than in ANT tissues (Figure 6(b)). Results of the qRT-PCR and western blot analysis confirmed that the miR-22-5p expression was significantly associated with reduced TOP2A levels in MHCC97L and BEL-7404 cells (Figures 6(c) and 6(d), Figure S4D). Subcellular localization analysis revealed that miR-22-5p was mainly expressed in the cytoplasm (Figure 6(e)). miR-22-5p mimics reduced the migration and invasion abilities of MHCC97L and Bel-7404 cells, but this inhibition was

3.6. TOP2A as a Direct Downstream Target of miR-22-5p.

Dysregulation of target gene expression in tumor cells is mainly due to the action of microRNA (miRNA) [17, 18]. Therefore, we explored whether miRNAs affect the HCC growth and metastasis by binding to TOP2A. First, we used miRNA target prediction tools to identify four potential miRNAs (has-miR-139-5p, has-miR-22-5p, has-miR-4683, and has-miR-582-3p) that might bind to TOP2A (Figure 6(a)). TCGA data showed that these candidate miRNAs had low expression in tumor tissues and high expression in ANT (Figure S4A). Patients with elevated levels of miR-139-5p and miR-22-5p had longer OS, while those with higher miR-582-3p levels had shorter OS (Figure S4B). No significant difference was observed in the expression of miR-4683 (Figure S4B). Only has-miR-22-5p

expression was associated with TOP2A levels (r = −0.223, P = 4.78e − 2; Figure S4C). The expression of the four miRNAs was lower in HCC tissues than in ANT tissues (Figure 6(b)). Results of the qRT-PCR and western blot analysis confirmed that the miR-22-5p expression was significantly associated with reduced TOP2A levels in MHCC97L and BEL-7404 cells (Figures 6(c) and 6(d), Figure S4D). Subcellular localization analysis revealed that miR-22-5p was mainly expressed in the cytoplasm (Figure 6(e)). miR-22-5p mimics reduced the migration and invasion abilities of MHCC97L and Bel-7404 cells, but this inhibition was

3.7. TOP2A Overexpression Reversing the Effect of miR-22-5p.

miR-22-5p inhibited the expression of TOP2A by binding to the 3′UTR of TOP2A mRNA. A decrease in the mRNA and protein levels of TOP2A was induced by miR-22-5p mimics. TOP2A overexpression reversed these effects (Figures 7(a) and 7(b)). The results of wound healing experiments showed that mi-22-5p inhibited the migration ability of MHCC97L and Bel-7404 cells, but this inhibition was reversed by the overexpression of TOP2A (Figure 7(c)). Likewise, TOP2A overexpression reversed the invasion-suppressive effect of miR-22-5p on MHCC97L and BEL-7404 cells (Figure 7(d)). Collectively, these results indicated that miR-22-5p downregulated the expression of TOP2A, thereby exerting a tumor suppressor effect. TOP2A overexpression reversed the effect of miR-22-5p.

Table 1: Information on the nine prospective drugs with significant scores for hepatocellular carcinoma treatment.

| Drug name | PubChem CID | Molecular formula | Classification | Docking score | SPa | XPb |
|-----------|-------------|-------------------|----------------|---------------|-----|-----|
| Trametinib| 11707110    | C_{26}H_{32}F_{12}N_{6}O_{4} | Protein kinase inhibitor | -6.885 | -6.885 | -4.976 |
| Selumetinib| 10127622   | C_{17}H_{18}BrCIF_{2}N_{4}O_{3} | Tyrosine kinase inhibitors | -6.164 | -6.172 | -6.844 |
| Refametinib (RDEA119)| 44182295 | C_{23}H_{23}F_{3}IN_{2}O_{5} | Inhibitor of mitogen-activated ERK kinase | -5.403 | -5.405 | -7.441 |
| PD-0352901 | 9826528 | C_{14}H_{11}F_{2}IN_{2}O_{4} | ERK MAPK signaling | -6.213 | -6.213 | -7.227 |
| Dabrafenib | 11707110 | C_{26}H_{23}F_{15}N_{5}O_{4} | Reversible ATP-competitive kinase inhibitor | -4.725 | -7.726 | -6.128 |
| Navitoclax | 24978538 | C_{17}H_{15}ClF_{3}N_{4}O_{4} | Bcl-2 antagonist | -7.429 | -7.588 | -5.757 |
| Teniposide | 452548 | C_{33}H_{32}O_{13}S | Topoisomerase II inhibitors | -4.725 | -4.726 | -4.803 |
| Etoposide | 36462 | C_{29}H_{32}O_{13} | Topoisomerase II inhibitors | -4.994 | -4.994 | -4.078 |
| Neopeltolide | 16115403 | C_{31}H_{46}N_{2}O_{9} | Inhibitor of mitochondrial ATP synthesis coupled proton transport | -5.752 | -5.752 | -5.216 |

SP: standard precision; XP: extraprecision.
Figure 8: Continued.

TOPO2A (3D)

(a)
3.8. Refametinib and Dabrafenib as Effective Drugs Targeting TOP2A. We explored the TOP2A interactions using the data obtained from the DrugBank for drug-protein effect analysis (Figure S5). Molecular docking showed that two TOP2A inhibitors, teniposide and etoposide, did not show high binding power, whereas refametinib (high extra precision)
and dabrafenib (high standard precision) showed stronger binding power and effect on TOP2A (Table 1, Figure 8). These results demonstrated that refametinib and dabrafenib can be used as potential targeted drugs for TOP2A.

4. Discussion

Inactivation of the Hippo signaling pathway is pivotal for cancer onset and progression. In this study, TOP2A was identified as an oncogenic gene that is highly expressed in HCC by inhibiting the Hippo signaling pathway. The upregulation of TOP2A, which promoted EMT, is responsible for the promotion of HCC cell invasion and migration. Mechanistically, TOP2A altered the invasiveness and migration of HCC cells through the Hippo signaling pathway. Moreover, the lack of miR-22-5p led to an abnormal increase in the levels of TOP2A expression in HCC cells. Taken together, our study unravels the hitherto unappreciated role of TOP2A in the Hippo signaling pathway.

Chromosomal instability (CIN) is a major feature of cancer cells and is associated with DNA unwinding and mutations and epigenetic modifications of repair genes (topoisomerase family genes) [6]. In the TCGA LIHC cohort, the mutation rate of TOP2 was much higher than that of TOP1 and TOP3. TOP2 is expressed in most eukaryotic organisms and has two isoforms, namely, TOP2A and TOP2B [19]. TOP2A is mainly active during DNA replication and mitosis [20], while TOP2B participates in the transcriptional regulation of gene expression [21]. In various types of tumors, including HCC, TOP2A shows huge expression differences. TOP2A expression is correlated with tumor resistance [22–24]. In 2019, Peng et al. [25] found that a small group of malignant cells from pancreatic ductal adenocarcinoma sample expressed MKI67, TOP2A, and CCNB1, and these cells showed a high degree of malignancy to promote tumor progression. TOP2A was dysregulated in other tumor types [26]. However, there are few studies on TOP2A in the field of liver cancer, all of which are bioinformatics research [27, 28]. In this study, we investigated the cancer-promoting effects of TOP2A on HCC. The overexpression of TOP2A stimulated the invasion and migration of HCC cells and accelerated the liver cancer progression.

In the WGCNA analysis, TOP2A was mainly associated with DNA replication. Consistent with the findings of this analysis, we observed that TOP2A overexpression in HCC cells upregulated the levels of Snail1 and Snail2 and increased those of N-cadherin and vimentin. TOP2A promotes EMT in HCC cells to increase their invasion and migration capabilities. Wang et al. [29] confirmed that TOP2A in cervical cancer promotes EMT in tumor cells through the PI3K/AKT signaling pathway, which leads to tumor metastasis. Collectively, these results illustrated that TOP2A enhances the motility of HCC cells through EMT.

KEGG enrichment and GSEA analysis were conducted to investigate the mechanism by which TOP2A promotes the HCC progression. Results showed that TOP2A and its related genes were enriched in the Hippo signaling pathway. The Hippo signaling pathway controls organ growth by suppressing cell growth and stimulating apoptosis. The dysregulation of the pathway often leads to uncontrolled cell division in various cancer types [30]. The Hippo pathway is crucial for the initiation of liver cancer [31]. Through the use of verteporfin (VP), we were able to perform cell experiments and further validate the connection between the TOP2A pathway and the Hippo pathway. VP is a photosensitizer of photodynamic therapy (PDT) and was identified as an inhibitor of the combination of YAP1 and TEAD4 [32]. We found that VP inhibits HCC cell invasion and migration induced by TOP2A overexpression. TOP2A promotes tumor progression through the Hippo pathway. Weiler et al. [33] found that activating YAP can induce CIN. Conversely, disrupting the interaction between YAP and TEAD4, the transcriptional coactivators of the Hippo signaling pathway, reduces the expression of CIN genes (including TOP2A). TOP2A affects the mobility of HCC cells through the Hippo signaling pathway.

Dysregulation of miRNAs occurs in most tumor cells [34]. miRNA and mRNA often form a complex ceRNA network to regulate the expression of oncogenes in tumors [35]. The level of miR-22-5p was relatively low in HCC tissues and reduced the TOP2A expression by binding to the mRNA 3’UTR region. Consistent with these reports, miR-22-5p mimics reduced the HCC cell proliferation, migration, and invasion, in addition to inducing apoptosis, which was rescued by the overexpression of TOP2A. Han et al. [36] found that MIR22HG upregulated the expression of miR-22-3p and miR-22-5p in the cytoplasm and affected the progression of gliomas via the Wnt/β-catenin signaling pathway. In summary, the reduction of miR-22-5p level in HCC cells may be the reason for the high TOP2A expression.

With the advancement of molecular structure determination technology, the use of molecular docking to identify specific binding drugs for target proteins has improved the efficiency of clinical translation [37]. To identify the application of TOP2A as a therapeutic target in HCC, we employ network pharmacology to identify drugs that can affect the TOP2A and predict the effective binding site. Anthracyclines can be applied to TOP2A, but their efficacy is mild [11]. We screened nine drugs that act on TOP2A to evaluate the receptor-ligand binding conformation and affinity through molecular docking. Results showed that dabrafenib and refametinib have higher TOP2A affinities compared with traditional anthracyclines. Therefore, we assessed the clinical benefits of dabrafenib and refametinib.

However, our study has some limitations. TOP2A plays a regulatory role in HCC via the Hippo signaling pathway, but its specific details have not been clearly explored. The key point of Hippo signaling pathway in which TOP2A acts through needs to be explored further. Furthermore, in vivo experiments should be conducted to elucidate this specific mechanism.

5. Conclusion

In summary, we have identified TOP2A as a crucial promoter of HCC progression. TOP2A affects HCC cell EMT
through the Hippo signaling pathway to promote HCC invasion and migration. High TOP2A expression levels were associated with a reduction in the expression of miR-22-5p. Therefore, TOP2A may be a biomarker for predicting the prognosis and a target for HCC therapy.

**Abbreviations**

PLC: Primary liver cancer  
HCC: Hepatocellular carcinoma  
TOP2A: DNA topoisomerases II-alpha  
ANT: Adjacent nontumor tissue  
CIN: Chromosomal instability  
mRNA: MicroRNA  
OS: Overall survival  
qRT-PCR: Quantitative real-time polymerase chain reaction  
EMT: Epithelial-mesenchymal transition  
AFP: Alpha-fetoprotein  
SCID mice: Severe combined immune deficient mice.

**Data Availability**

On reasonable request, the corresponding authors provided access to all data collected and/or analyzed during this investigation.

**Ethical Approval**

The IRB at Shanxi Bethune Hospital gave its approval to all of the experiments regarding human tumor samples and mice (no.: SBQLL-2020-038).

**Conflicts of Interest**

The authors have stated no competing interests.

**Authors’ Contributions**

HC.Z. and C.C. conceived and conducted experiments and wrote the manuscript. H.S., R.Q., and Y.T. conducted experiments and data analysis. X.W., F.L., and Q.H. produced and identified mice with changed genomes. J.H. and Y.L. supplied human specimens. HL.Z. and Y.L. started and designing the research. HL.Z. initiated the investigation and coordinated and drafted the paper. The author(s) have reviewed the manuscript and given their final approval. Haichao Zhao and Changzhou Chen contributed equally to this work and co-first authors.

**Acknowledgments**

We would like to acknowledge Changyu Chen (School of Foreign Languages, Xiangtan University) and BioRender.com for their contributions to the language editing of this article and creation of the figures used in the study, respectively. We would also like to acknowledge Helixlife for providing experimental and technological support. The research was supported by the Shanxi Science and Technology office (Nos. 201903D421026 and 201901D1111404), Shanxi Educational Department (No. 2021Y359), and Shanxi ‘136’ Leading Clinical Key Specialty (No. 2019XY002).

**Supplementary Materials**

Table S1: fluorescent primer sequences. Table S2: baseline data table based on TOP2A expression from TCGA. Table S3: single/multiple logistic regression analysis of factors associated with TOP2A. Figure S1: the expression of TOP2A in 33 kinds of tumors. TOPs are unregulated in most tumors, and TOP2A is present in HCC patients. (A) Pan-cancer expression of TOP1. (B) Pan-cancer expression of TOP2A. (C) Pan-cancer expression of TOP2B. (D) Pan-cancer expression of TOP3A. (E) Pan-cancer expression of TOP3B. Figure S2: TOP2A expression between cancer and normal tissues in HCC. (A) Violin chart showed the expression of TOP2A mRNA in primary HCC tissues and normal tissues (TCGA). (B) Connection diagram showed the expression of TOP2A mRNA in 50 paired samples. (C) Box plot showed the expression of TOP2A mRNA in primary HCC tissues and normal tissues (TCGA+GTEx). (D) Box plot showed the association between TOP2A expression and histologic grade. (E) Box plot showed the association between TOP2A expression and disease progression. (F) Box plot showed the association between TOP2A expression and tumor stage (Kaplan-Meier survival curves showed Overall survival comparing the high and low expression of TOP2A in HCC patients. (K) Kaplan-Meier survival curves showed disease-specific survival comparing the high and low expression of TOP2A in HCC patients. (L) Kaplan-Meier survival curves showed progression-free interval comparing the high and low expressions of TOP2A in HCC patients. Data are shown as mean ± SEM; ***P < 0.001, **P < 0.01, and *P < 0.05.

Figure S3: correlation of key proteins in TOP2A and Hippo signaling pathway (ENCORI). (A) Correlation of TOP2A and LAST1 expression in LIHC. (B) Correlation of TOP2A and LAST2 expression in LIHC. (C) Correlation of TOP2A and YAP1 expression in LIHC. (D) Correlation of TOP2A and TAZ expression in LIHC. (E) Correlation of TOP2A and TEAD4 expression in LIHC. (F) Box plot showed the expression of miRNAs (has-miR-139-5p, has-miR-22-5p, has-miR-4683, and has-miR-582-3p) in primary HCC tissues and normal tissues of LIHC (TCGA). (B) Kaplan-Meier survival curves showed overall survival comparing the high and low expression of miRNAs (has-miR-139-5p, has-miR-22-5p, has-miR-4683, and has-miR-582-3p) in HCC patients. (C) Correlation of TOP2A and miRNAs (has-miR-139-5p, has-miR-22-5p, has-miR-4683, and has-miR-582-3p) expression in 374 LIHC samples (ENCORI). (D) qRT-PCR showed that
the expression level of TOP2A mRNA was in the HCC cell line (7404) transfected with miRNAs. Data are shown as mean ± SEM; ***P < 0.001, **P < 0.01, and *P < 0.05. Figure S5: 2D images of drugs that can work with TOP2A (DrugBank). (Supplementary Materials)

References

[1] F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and A. Jemal, "Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries," CA: A Cancer Journal for Clinicians, vol. 68, no. 6, pp. 394–424, 2018.

[2] X.-L. Gong and S.-K. Qin, "Progress in systemic therapy of advanced hepatocellular carcinoma," World Journal of Gastroenterology, vol. 22, no. 29, pp. 6582–6594, 2016.

[3] A. Vitale, M. Peck-Radosavljevic, E. G. Giannini et al., "Personalized treatment of patients with very early hepatocellular carcinoma," Journal of Hepatology, vol. 66, no. 2, pp. 412–423, 2017.

[4] J. Huang, V. Lok, C. H. Ngai et al., "Disease burden, risk factors, and recent trends of liver cancer: a global country-level analysis," Liver Cancer, vol. 10, no. 4, pp. 330–345, 2021.

[5] T. J. Wendorff, B. H. Schmidt, P. Heslop, C. A. Austin, and J. M. Berger, "The structure of DNA-bound human topoisomerase II alpha: conformational mechanisms for coordinating inter-subunit interactions with DNA cleavage," Journal of Molecular Biology, vol. 424, no. 3–4, pp. 109–124, 2012.

[6] T. Chen, Y. Sun, P. Ji, S. Kopetz, and W. Zhang, "Topoisomerase IIα in chromosome instability and personalized cancer therapy," Oncogene, vol. 34, no. 31, pp. 4019–4031, 2015.

[7] L. Ren, J. Liu, K. Gou, and C. Xing, "Copy number variation and high expression of DNA topoisomerase II alpha predict worse prognosis of cancer: a meta-analysis," Journal of Cancer, vol. 9, no. 12, pp. 2082–2092, 2018.

[8] D. J. Burgess, J. Doles, L. Zender et al., "Topoisomerase levels determine chemotherapy response in vitro and in vivo," Proceedings of the National Academy of Sciences, vol. 105, no. 26, pp. 9053–9058, 2008.

[9] F. Kou, H. Sun, L. Wu et al., "TOP2A promotes lung adenocarcinoma cells’ malignant progression and predicts poor prognosis in lung adenocarcinoma," Journal of Cancer, vol. 11, no. 9, pp. 2496–2508, 2020.

[10] X. H. Gao, Z. Q. Yu, C. Zhang, C. G. Bai, J. M. Zheng, and C. G. Fu, "DNA topoisomerase II alpha: a favorable prognostic factor in colorectal cancer," International Journal of Colorectal Disease, vol. 27, no. 4, pp. 429–435, 2012.

[11] L. Orlando, B. Del Curto, S. Gandini et al., "Topoisomerase Ialpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her 2/neu-positive breast cancer," Breast, vol. 17, no. 5, pp. 506–511, 2008.

[12] H. Yan, C.-C. Yu, S. A. Fine et al., "Loss of the wild-type KRAS allele promotes pancreatic cancer progression through functional activation of YAP1," Oncogene, vol. 40, no. 50, pp. 6759–6771, 2021.

[13] Y. Zhang, L.-J. He, L.-L. Huang et al., "Oncogenic PAX6 elicits CDK4/6 inhibitor resistance by epigenetically inactivating the LATS2-Hippo signaling pathway," Clinical and Translational Medicine, vol. 11, no. 8, article e503, 2021.

[14] I. M. Moya, S. A. Castaldo, L. van den Mooter et al., "Peritumoral activation of the Hippo pathway effectors YAP and TAZ suppresses liver cancer in mice," Science, vol. 366, no. 6468, pp. 1029–1034, 2019.

[15] A. U. Schirmer, L. M. Driver, M. T. Zhao et al., "Non-canonical role of Hippo tumor suppressor serine/threonine kinase 3 STK3 in prostate cancer," Molecular therapy: the journal of the American Society of Gene Therapy, vol. 30, no. 1, pp. 485–500, 2022.

[16] C. Wang, X. Zhu, W. Feng et al., "Verteporfin inhibits YAP function through up-regulating 14-3-3ζ sequestering YAP in the cytoplasm," American Journal of Cancer Research, vol. 6, no. 1, pp. 27–37, 2016.

[17] S.-L. Zhou, Z.-Q. Hu, Z.-J. Zhou et al., "miR-28-5p-IL-34-macrophase feedback loop modulates hepatocellular carcinoma metastasis," Hepatology, vol. 63, no. 5, pp. 1560–1575, 2016.

[18] S.-L. Zhou, D. Yin, Z.-Q. Hu et al., "A positive feedback loop between cancer stem-like cells and tumor-associated neutrophils controls hepatocellular carcinoma progression," Hepatology, vol. 70, no. 4, pp. 1214–1230, 2019.

[19] M. Tsai-Pflugfelder, L. F. Liu, A. A. Liu et al., "Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22," Proceedings of the National Academy of Sciences, vol. 85, no. 19, pp. 7177–7181, 1988.

[20] P. Grue, A. Grässer, M. Sehested et al., "Essential mitotic functions of DNA topoisomerase IIα are not adopted by topoisomerase IIβ in human H69 cells," Journal of Biological Chemistry, vol. 273, no. 50, pp. 33660–33666, 1998.

[21] Y. L. Lyu, C.-P. Lin, A. M. Azarova, L. Cai, J. C. Wang, and L. F. Liu, "Role of topoisomerase Ibβ in the expression of developmentally regulated genes," Molecular and Cellular Biology, vol. 26, no. 21, pp. 7929–7941, 2006.

[22] C. Zhu, L. Zhang, S. Zhao et al., "UPF1 promotes chemoresistance to oxaliplatin through regulation of TOP2A activity and maintenance of stemness in colorectal cancer," Cell Death & Disease, vol. 12, no. 6, p. 519, 2021.

[23] E. Kaplan and U. Gündüz, "Expression analysis of TOP2A, MSH2 and MLH1 genes in MCF7 cells at different levels of etoposide resistance," Biomedicine & Pharmacotherapy, vol. 66, no. 1, pp. 29–35, 2012.

[24] A. S. Betof, Z. N. Rabbani, M. E. Hardee et al., "Carbonic anhydrase IX is a predictive marker of doxorubicin resistance in early-stage breast cancer independent of HER2 and TOP2A amplification," British Journal of Cancer, vol. 106, no. 5, pp. 916–922, 2012.

[25] J. Peng, B.-F. Sun, C.-Y. Chen et al., "Single-cell RNA-seq highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinoma," Cell Research, vol. 29, no. 9, pp. 725–738, 2019.

[26] M. Jain, L. Zhang, M. He, Y.-Q. Zhang, M. Shen, and E. Kebebew, "TOP2A is overexpressed and is a therapeutic target for adenocortical carcinoma," Endocrine-Related Cancer, vol. 20, no. 3, pp. 361–370, 2013.

[27] H. Cai, B. Shao, Y. Zhou, and Z. Chen, "High expression of TOP2A in hepatocellular carcinoma is associated with disease progression and poor prognosis," Oncology Letters, vol. 20, no. 5, p. 1, 2020.

[28] Y. Zeng, H. He, Y. Zhang, X. Wang, L. Yang, and Z. An, "CCNB2, TOP2A, and ASPM reflect the prognosis of..."
hepatocellular carcinoma, as determined by weighted gene coexpression network analysis,” *Bio Med Research International*, vol. 2020, article 4612158, 2020.

[29] B. Wang, Y. Shen, Y. Zou et al., ”TOP2A promotes cell migration, invasion and epithelial-mesenchymal transition in cervical cancer via activating the PI3K/AKT signaling,” *Cancer Management and Research*, vol. 12, pp. 3807–3814, 2020.

[30] D. Pan, ”Hippo signaling in organ size control,” *Genes & Development*, vol. 21, no. 8, pp. 886–897, 2007.

[31] Q. Liu, J. Li, W. Zhang et al., ”Glycogen accumulation and phase separation drives liver tumor initiation,” *Cell*, vol. 184, pp. 5559–5576.e19, 2021.

[32] K. Brodowska, A. Al-Moujahed, A. Marmalidou et al., ”The clinically used photosensitizer verteporfin (VP) inhibits YAP-T ÉAD and human retinoblastoma cell growth in vitro without light activation,” *Experimental Eye Research*, vol. 124, pp. 67–73, 2014.

[33] S. M. E. Weiler, F. Pinna, T. Wolf et al., ”Induction of chromosome instability by activation of Yes-associated protein and Forkhead Box M1 in liver cancer,” *Gastroenterology*, vol. 152, pp. 2037–2051.e22, 2017.

[34] J. K. Palanichamy and D. S. Rao, ”miRNA dysregulation in cancer: towards a mechanistic understanding,” *Frontiers in Genetics*, vol. 5, p. 54, 2014.

[35] X. Zhu, L. Jiang, H. Yang, T. Chen, X. Wu, and K. Lv, ”Analyzing the lncRNA, miRNA, and mRNA-associated ceRNA networks to reveal potential prognostic biomarkers for glioblastoma multiforme,” *Cancer Cell International*, vol. 20, no. 1, p. 393, 2020.

[36] M. Han, S. Wang, S. Fritah et al., ”Interfering with long non-coding RNA MIR22HG processing inhibits glioblastoma progression through suppression of Wnt/β-catenin signalling,” *Brain*, vol. 143, no. 2, pp. 512–530, 2020.

[37] D. A. Gschwend, A. C. Good, and I. D. Kuntz, ”Molecular docking towards drug discovery,” *Journal of Molecular Recognition*, vol. 9, no. 2, pp. 175–186, 1996.